P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL‐DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL.

Autor:	Zinzani, P. L., Ansell, S. M., Bosch, F., Friedberg, J. W., Marolleau, J. P., Arcaini, L., Garcia‐Sanz, R., Gopal, A. K., Grande, C., Merryman, R., Pinto, A., Smith, S. D., Villasboas, J. C., Wallace, D., Fagerberg, J., Magalhaes, J. G., Armand, P.
Zdroj:	HemaSphere; 2022 Supplement 3, Vol. 6, p1005-1006, 2p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text